EP Patent

EP0518675A2 — Cyclic renin inhibitors

Assigned to Merck and Co Inc · Expires 1992-12-16 · 33y expired

What this patent protects

Compounds of the formula : are disclosed. These compounds inhibit the angiotensinogen-cleaving action of the natural proteolytic enzyme, renin, and are useful in treating, preventing or managing renin-associated hypertension, hyperaldosteronism, congestive heart failure, …

USPTO Abstract

Compounds of the formula : are disclosed. These compounds inhibit the angiotensinogen-cleaving action of the natural proteolytic enzyme, renin, and are useful in treating, preventing or managing renin-associated hypertension, hyperaldosteronism, congestive heart failure, and glaucoma.

Drugs covered by this patent

Patent Metadata

Patent number
EP0518675A2
Jurisdiction
EP
Classification
—
Expires
1992-12-16
Drug substance claim
No
Drug product claim
No
Assignee
Merck and Co Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.